News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Panel Mixed on King Pharmaceuticals┬«, Inc., Pain Therapeutics (PTIE) Drug; FDA Scheduled to Act By December 10 Under Six-Month Priority Review


11/14/2008 7:16:12 AM

Nov. 13 (Bloomberg) -- Pain Therapeutics Inc. and King Pharmaceuticals Inc.'s experimental pain pill Remoxy is less susceptible to abuse than Purdue Pharma LP's OxyContin, members of a U.S. panel said, suggesting the drug will win approval.

Read at Reuters
Read at Pharmalot
Read at Bloomberg
Read at San Francisco Business Times
Read at AP


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES